It only has to confirm its insufficient manufacturing capacity for pharmaceuticals if it is no LDC. Referring to the 2016 transition period for LDCs, the Government announced that it would no longer enforce patent rights that could have previously been granted on the triple combined fixed-dose anti-retroviral drug TriAvir.462 Between September 2008 and September 2009, Rwanda imported 260,000 packs of TriAvir as manufactured in Canada by Apotex Inc.463 As an LDC, Rwanda did not have to prove its lack of manufacturing capacity. On the quantity of imported medicines, see WTO document IP/N/9/RWA/1.